Thirty-eight women with early stage breast cancer were treated withRosi for 2–6 weeks withtumor growth inhibition or progression as an end point [36].The data indicate that short-term Rosi therapy in early-stage breast cancerpatients has both local and systemic effects on PPARγ signaling. This evidence concerns the gene PPARG and breast cancer.